Gemcitabine plus Capecitabine

DRUG2 trials

Sponsors

Asan Medical Center, Shanghai Zhongshan Hospital

Conditions

Borderline Resectable Pancreatic CancerHigh-Risk Resectable Pancreatic CancerPancreatic Cancer

Phase 2

Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer

CompletedNCT01268384

Asan Medical CenterPancreatic Cancer

Start: 2006-04-30End: 2011-08-31Updated: 2011-12-06

Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC

Not yet recruitingNCT07833241

Shanghai Zhongshan HospitalBorderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer

Start: 2026-09-01End: 2029-09-01Target: 56Updated: 2026-09-22